vs
Side-by-side financial comparison of QuidelOrtho Corp (QDEL) and StoneX Group Inc. (SNEX). Click either name above to swap in a different company.
StoneX Group Inc. is the larger business by last-quarter revenue ($1.2B vs $619.8M, roughly 1.9× QuidelOrtho Corp). StoneX Group Inc. runs the higher net margin — 11.6% vs -14.8%, a 26.4% gap on every dollar of revenue. On growth, StoneX Group Inc. posted the faster year-over-year revenue change (81.0% vs -10.5%). Over the past eight quarters, StoneX Group Inc.'s revenue compounded faster (53.5% CAGR vs -6.6%).
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
StoneX Group Inc. is an American financial services company. The company operates in six areas: commercial hedging, global payments, securities, physical commodities, foreign exchange and clearing and execution services (CES).
QDEL vs SNEX — Head-to-Head
Income Statement — Q1 FY2027 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $619.8M | $1.2B |
| Net Profit | $-91.8M | $139.0M |
| Gross Margin | — | — |
| Operating Margin | — | 15.4% |
| Net Margin | -14.8% | 11.6% |
| Revenue YoY | -10.5% | 81.0% |
| Net Profit YoY | — | 63.3% |
| EPS (diluted) | $-1.35 | $2.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $619.8M | — | ||
| Q4 25 | — | $1.2B | ||
| Q3 25 | $699.9M | $32.7B | ||
| Q2 25 | $613.9M | $851.2M | ||
| Q1 25 | $692.8M | $820.4M | ||
| Q4 24 | $707.8M | $663.1M | ||
| Q3 24 | $727.1M | $31.1B | ||
| Q2 24 | $637.0M | $571.8M |
| Q1 26 | $-91.8M | — | ||
| Q4 25 | — | $139.0M | ||
| Q3 25 | $-733.0M | $85.7M | ||
| Q2 25 | $-255.4M | $63.4M | ||
| Q1 25 | $-12.7M | $71.7M | ||
| Q4 24 | $-178.4M | $85.1M | ||
| Q3 24 | $-19.9M | $76.7M | ||
| Q2 24 | $-147.7M | $61.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 3.7% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.0% | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 15.4% | ||
| Q3 25 | -100.7% | 0.3% | ||
| Q2 25 | -29.4% | -1.3% | ||
| Q1 25 | 4.7% | -1.0% | ||
| Q4 24 | -14.2% | -3.2% | ||
| Q3 24 | 2.1% | -0.0% | ||
| Q2 24 | -18.4% | -4.7% |
| Q1 26 | -14.8% | — | ||
| Q4 25 | — | 11.6% | ||
| Q3 25 | -104.7% | 0.3% | ||
| Q2 25 | -41.6% | 7.4% | ||
| Q1 25 | -1.8% | 8.7% | ||
| Q4 24 | -25.2% | 12.8% | ||
| Q3 24 | -2.7% | 0.2% | ||
| Q2 24 | -23.2% | 10.8% |
| Q1 26 | $-1.35 | — | ||
| Q4 25 | — | $2.50 | ||
| Q3 25 | $-10.78 | $0.72 | ||
| Q2 25 | $-3.77 | $1.22 | ||
| Q1 25 | $-0.19 | $1.41 | ||
| Q4 24 | $-2.54 | $1.69 | ||
| Q3 24 | $-0.30 | $2.32 | ||
| Q2 24 | $-2.20 | $1.25 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $140.4M | $1.6B |
| Total DebtLower is stronger | $2.5B | — |
| Stockholders' EquityBook value | $1.9B | $2.5B |
| Total Assets | $5.6B | $47.8B |
| Debt / EquityLower = less leverage | 1.33× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $140.4M | — | ||
| Q4 25 | — | $1.6B | ||
| Q3 25 | $98.1M | $1.6B | ||
| Q2 25 | $151.7M | $1.3B | ||
| Q1 25 | $127.1M | $1.3B | ||
| Q4 24 | $98.3M | $1.4B | ||
| Q3 24 | $143.7M | $1.3B | ||
| Q2 24 | $107.0M | $1.2B |
| Q1 26 | $2.5B | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.1B | — | ||
| Q1 25 | $2.1B | — | ||
| Q4 24 | $2.1B | — | ||
| Q3 24 | $2.2B | — | ||
| Q2 24 | $2.2B | — |
| Q1 26 | $1.9B | — | ||
| Q4 25 | — | $2.5B | ||
| Q3 25 | $2.0B | $2.4B | ||
| Q2 25 | $2.8B | $2.0B | ||
| Q1 25 | $3.0B | $1.9B | ||
| Q4 24 | $3.0B | $1.8B | ||
| Q3 24 | $3.2B | $1.7B | ||
| Q2 24 | $3.2B | $1.6B |
| Q1 26 | $5.6B | — | ||
| Q4 25 | — | $47.8B | ||
| Q3 25 | $5.7B | $45.3B | ||
| Q2 25 | $6.4B | $34.3B | ||
| Q1 25 | $6.5B | $31.3B | ||
| Q4 24 | $6.4B | $29.6B | ||
| Q3 24 | $6.8B | $27.5B | ||
| Q2 24 | $6.7B | $25.9B |
| Q1 26 | 1.33× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 1.23× | — | ||
| Q2 25 | 0.74× | — | ||
| Q1 25 | 0.70× | — | ||
| Q4 24 | 0.72× | — | ||
| Q3 24 | 0.68× | — | ||
| Q2 24 | 0.70× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-1.3B |
| Free Cash FlowOCF − Capex | — | $-1.3B |
| FCF MarginFCF / Revenue | — | -106.4% |
| Capex IntensityCapex / Revenue | — | 1.3% |
| Cash ConversionOCF / Net Profit | — | -9.08× |
| TTM Free Cash FlowTrailing 4 quarters | — | $3.5B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $-1.3B | ||
| Q3 25 | $-45.5M | $3.5B | ||
| Q2 25 | $-46.8M | $1.5B | ||
| Q1 25 | $65.6M | $-154.5M | ||
| Q4 24 | $63.7M | $-477.8M | ||
| Q3 24 | $117.9M | $192.6M | ||
| Q2 24 | $-97.9M | $-622.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | $-1.3B | ||
| Q3 25 | $-94.7M | $3.5B | ||
| Q2 25 | $-84.3M | $1.5B | ||
| Q1 25 | $9.4M | $-169.8M | ||
| Q4 24 | $16.5M | $-491.4M | ||
| Q3 24 | $71.4M | $175.9M | ||
| Q2 24 | $-133.2M | $-640.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | -106.4% | ||
| Q3 25 | -13.5% | 10.7% | ||
| Q2 25 | -13.7% | 173.3% | ||
| Q1 25 | 1.4% | -20.7% | ||
| Q4 24 | 2.3% | -74.1% | ||
| Q3 24 | 9.8% | 0.6% | ||
| Q2 24 | -20.9% | -112.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.3% | ||
| Q3 25 | 7.0% | 0.1% | ||
| Q2 25 | 6.1% | 1.9% | ||
| Q1 25 | 8.1% | 1.9% | ||
| Q4 24 | 6.7% | 2.1% | ||
| Q3 24 | 6.4% | 0.1% | ||
| Q2 24 | 5.5% | 3.2% |
| Q1 26 | — | — | ||
| Q4 25 | — | -9.08× | ||
| Q3 25 | — | 41.18× | ||
| Q2 25 | — | 23.52× | ||
| Q1 25 | — | -2.15× | ||
| Q4 24 | — | -5.61× | ||
| Q3 24 | — | 2.51× | ||
| Q2 24 | — | -10.05× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
QDEL
| Labs | $353.1M | 57% |
| Immunohematology | $138.3M | 22% |
| Point of Care | $112.8M | 18% |
| Molecular Diagnostics | $7.8M | 1% |
SNEX
Segment breakdown not available.
